Zanolimumab

Zanolimumab
Monoclonal antibody
Type Whole antibody
Source Human
Target CD4
Identifiers
CAS Number 652153-01-0 N
ATC code none
ChemSpider none
UNII HG3L8885M0 YesY
KEGG D06356 YesY
Chemical data
Molar mass 147 kg/mol
 NYesY (what is this?)  (verify)

Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] The drug is currently undergoing Phase II trials.[5]

References

  1. ↑ Genmab initiates Phase II Study with HuMax-CD4
  2. ↑ http://www.tenxbiopharma.com/development.shtml
  3. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
  4. ↑ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
  5. ↑ "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.


This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.